| Name | Title | Contact Details |
|---|
Caron Products is a provider of incubators & chambers for cell growth and product environmental testing in biological research, scale-up culture, and drug and biological QA/QC testing. Caron`s products are integral to workflows ranging from cell & gene therapy to medical device manufacturing. Caron`s expanding resources, with manufacturing facilities in both the USA and Europe, and a worldwide network of sales and service personnel aligns with the needs of the global biomedical industry.
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.
At Precision for Medicine, we help our pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products. Backed by a diverse team of experts across the spectrum of the healthcare marketplace, we provide a comprehensive and integrated set of services that help accelerate research, enable market adoption, enhance patient outcomes, and realize the full commercial potential of new therapies and products.
The Heritage of Life Sciences Products HLS Therapeutics is about maintaining the heritage of life science products. We are dedicated to keeping trusted branded drugs on the market. HLS provides access to medications critical to Health Care Providers, patients and their caregivers with the high-quality brand names they trust. HLS Therapeutics Inc. is a specialty pharmaceutical company dedicating itself to acquiring and distributing commercial stage mature, or legacy, branded pharmaceutical drugs for the North American markets. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success. Building on the expertise of our founders, HLS is focused on treatment products for the central nervous system, soon to be followed by specialty products in other therapeutic areas. HLS Therapeutics focuses on the North American market and has operational locations in Toronto (Etobicoke, Ontario), and Philadelphia (Rosemont, Pennsylvania), We source our products from the drug`s originator or from best-in-class manufacturing partners, ensuring our brands are manufactured with the highest standards of quality and in compliance with FDA and Health Canada`s regulations. HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycle during and post exclusivity, providing access to treatments critical to Health Care Providers, patients and their caregivers with the brand names they trust.
Chugai Pharma USA (CPUSA), a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.(Chugai) located in Berkeley Heights NJ, is focused on early stage clinical research, mainly in the disease areas of oncology, renal disease, and bone and joint disease. CPUSA operates as part of Chugai`s Translational Clinical Research Division (TCRD), a global function with offices in Europe, Japan and the U.S. TCRD is dedicated to late pre-clinical and early clinical development of Chugai-originated pipeline products. TCRD aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to global development stage and ultimately to market, as efficiently as possible. Chugai`s specific focus is placed on bringing innovative therapies to market for conditions where treatment options may be limited and patient needs may be unmet. Chugai works in strategic alliance with Roche to pursue cutting-edge biopharmaceutical, antibody, and molecular-targeted research technologies-areas that constitute Chugai`s greatest strengths-as well as chemical synthesis technology. Chugai has achieved success with its original products and will continue to seek to provide exceptional value to patients. As a most important member of the Roche group, Chugai aims to become a top pharmaceutical company by providing a continuous flow of innovative new medicines internationally. CPUSA believes in success through collaboration, and our culture encourages innovation through sharing ideas. If being on the cutting edge of translational clinical research and development appeals to you, consider a career with CPUSA.